Abstract |
Dissemination of tumour cells and the development of solid metastases occurs via blood vessels and lymphatics. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) can be detected in venous blood in patients with early and metastatic breast cancer, and their prognostic relevance has been demonstrated on numerous occasions. Repeated testing for CTCs and ctDNA, or regular so-called "liquid biopsy", can be performed easily at any stage during the course of disease. Additional molecular analysis allows definition of tumour characteristics and heterogeneity that may be associated with treatment resistance. This in turn makes personalised, targeted treatments possible that may achieve both improved overall survival and quality of life.
|
Authors | Arkadius Polasik, Marie Tzschaschel, Fabienne Schochter, Amelie de Gregorio, Thomas W P Friedl, Brigitte Rack, Andreas Hartkopf, Peter A Fasching, Andreas Schneeweiss, Volkmar Müller, Jens Huober, Wolfgang Janni, Tanja Fehm |
Journal | Geburtshilfe und Frauenheilkunde
(Geburtshilfe Frauenheilkd)
Vol. 77
Issue 12
Pg. 1291-1298
(Dec 2017)
ISSN: 0016-5751 [Print] Germany |
PMID | 29269956
(Publication Type: Journal Article)
|